ImmuPharma PLC's (LON:IMM) Tim McCarthy caught up with Proactive London's Andrew Scott soon after the firm announced it had raised £1.5mln from a share subscription to fund an expansion of its research & development programmes.
The funding comprises a £200,000 share subscription by the company’s president and chief scientific officer Robert Zimmer as well as £1.3mln from Lanstead Capital - an institutional investor and significant shareholder in the business.
Its US partner, Avion Pharmaceuticals, is strengthening its advisory team for the phase III trial of its Lupuzor lupus treatment plus ImmuPharma's also planning a proof of concept study for Lupuzor in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
